Thomas Eigentler
Humboldt-Universität zu Berlin(DE)University Children's Hospital Tübingen(DE)Charité - Universitätsmedizin Berlin(DE)
Publications by Year
Research Areas
Cutaneous Melanoma Detection and Management, Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, Immunotherapy and Immune Responses, CAR-T cell therapy research
Most-Cited Works
- → Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial(2015)1,554 cited
- → Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy(2016)638 cited
- → Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial(2020)638 cited
- → Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects(2011)578 cited
- → Epidemiology of Skin Cancer(2014)563 cited
- → Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy(2016)556 cited